(9ci)-1H-茚-3-羧酰胺 | 74844-01-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚和异茚
• 中文名称: (9ci)-1H-茚-3-羧酰胺
• 英文名称: 1H-indene-3-carboxamide
• 英文别名: indene-3-carboxamide；Inden-3-carbamid；3H-indene-1-carboxamide
• CAS: 74844-01-2
• 化学式: C₁₀H₉NO
• mdl: MFCD01313391
• 分子量: 159.188
• InChiKey: CIGBERQUNYDMHH-UHFFFAOYSA-N

物化性质

• 熔点：
  195-212 °C (decomp)
• 沸点：
  408.2±43.0 °C(Predicted)
• 密度：
  1.241±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (9ci)-1H-茚-3-羧酰胺 在 phosphorus pentoxide 、 silica gel 作用下， 135.0~137.0 ℃ 、933.25 Pa 条件下， 以45%的产率得到3-cyanoindene
  参考文献：
  名称：

  Cycloaddition reactions of indenes. 2. Reactions with dimethyl acetylenedicarboxylate and maleic anhydride

  摘要：

  DOI：

  10.1021/jo01311a003
• 作为产物：
  描述：

  ethyl 1H-indene-3-carboxylate 在 乙醇 、 氨 作用下， 生成 (9ci)-1H-茚-3-羧酰胺
  参考文献：
  名称：

  Wislicenus; Hentrich, Justus Liebigs Annalen der Chemie, 1924, vol. 436, p. 20

  摘要：

  DOI：

文献信息

• [EN] SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF-BETA AND METHODS OF TREATMENT<br/>[FR] IMIDAZOLES SUBSTITUÉS POUR L'INHIBITION DE TGF-BÊTA ET MÉTHODES DE TRAITEMENT
  申请人：CLAVIUS PHARMACEUTICALS LLC

  公开号：WO2020041562A1

  公开（公告）日：2020-02-27

  This disclosure relates to low molecular weight substituted imidazoles that inhibit the TGF-b signaling pathway. More specifically, this disclosure relates to methods of using said imidazoles for the treatment of diseases related to the TGF-b signaling pathways including, but not limited to, atherosclerosis, Marfan syndrome, Loeys-Dietz syndrome, obesity, diabetes, multiple sclerosis, keratoconus, idiopathic pulmonary fibrosis, Alzheimer's Disease, chronic kidney disease, and scleroderma.

  这项披露涉及抑制TGF-b信号通路的低分子量取代咪唑化合物。更具体地，这项披露涉及使用上述咪唑化合物治疗与TGF-b信号通路相关的疾病的方法，包括但不限于动脉粥样硬化、马凡综合征、洛伊斯-迪茨综合征、肥胖症、糖尿病、多发性硬化、圆锥角膜、特发性肺纤维化、阿尔茨海默病、慢性肾病和硬皮病。
• Kinase Inhibitors
  申请人：Van Rompaey Philippe

  公开号：US20090233960A1

  公开（公告）日：2009-09-17

  The present invention relates to new AGC kinase inhibitors, in particular to compounds of Formula I, II, or III or a stereoisomer, tautomer, racemic, metabolite, pro- or predrug, salt, hydrate, or solvate thereof, I II III wherein X, R 1 , R 2 , R 3 , R 31 , n, and m have the meaning defined in the claims. In particular, the present invention relates more specifically to ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease.

  本发明涉及新的AGC激酶抑制剂，特别是公式I、II或III的化合物，或其立体异构体、互变异构体、外消旋体、代谢产物、前药或前制品、盐、水合物或溶剂化物，其中X、R1、R2、R3、R31、n和m在权利要求书中定义。特别地，本发明更具体地涉及ROCK抑制剂，包括这些抑制剂的组合物，特别是制药组合物，以及在治疗和预防疾病中使用这些抑制剂的用途。
• Short children with familial short stature show enhancement of somatotroph secretion but normal IGF-I levels
  作者：S. Bellone、G. Corneli、J. Bellone、C. Baffoni、S. Rovere、C. de Sanctis、G. Bona、E. Ghigo、G. Aimaretti

  DOI：10.1007/bf03344032

  日期：2002.5

  The aim of the present study was to evaluate the GH status in children with familial, idiopathic short stature (FSS). To this goal we evaluated the GH response to GHRH (1 mug/kg iv) + arginine (ARG) (0.5 g/kg iv) test which is one of the most potent and reproducible provocative tests of somatotroph secretion, in 67 children with FSS [50 boys and 17 girls, age 10.8+/-0.4 yr, pubertal stages I-III, height between -3.6 and -1.6 standard deviation score (SDS), target height <10'degrees centile, normality Of both spontaneous and stimulated GH secretion as well as of IGF-I levels]. The results in FSS were compared with those in groups of children of normal height (NHC) (42 NHC, 35 boys and 7 girls, age 12.0 +/- 0.5 yr, pubertal stages I-III, height between -1.3 and 1.4 SDS, height velocity standard deviation score (HVSDS)>25degrees centile, GH peak >20 mug/l after GHRH+ARG test, mean GH concentration [mGHc]>3 mug/l) and children with organic GH deficiency (GHD) (38 GHD, 29 boys and 9 girls, age 11.2+/-3.7 yr, pubertal stages I-III, height between -5.7 and -1.3 SDS, GH peak <20 mu g/l after GHRH +ARG test, mGHc <3 mg/l). Basal IGF-I levels and mGHc were also evaluated in each group over 8 nocturnal hours. IGF-I levels in FSS (209.2+/-15.6 mug/l) were similar to those in NHC (237.2+/-17.2 mug/l) and both were higher (p<0.0001) than those in GHD (72.0 +/- 4.0 mu g/l). The GH response to GHRH +ARG test in FSS (peak: 66.4 +/- 5.6 mu g/l) was very marked and higher (p<0.01) than that in NHC (53.3+/-4.5 mug/l) which, in turn, was higher (p<0.01) than in GHD (8.2 +/- 0.8 mu g/l). Similarly, the mGHc in FSS was higher than in NHC (6.7 +/- 0.5 mu g/l vs 5.1 +/- 0.7 mu g/l, p<0.05) which, in turn, was higher than in GHD (1.5+/-0.2 mug/l, p<0.0001). In conclusion, our present study demonstrates that short children with FSS show enhancement of both basal and stimulated GH secretion but normal IGF-I levels. These findings suggest that increased somatotroph function would be devoted to maintain normal IGF-I levels thus reflecting a slight impairment of peripheral GH sensitivity in FSS.
• Cycloaddition reactions of indenes. 2. Reactions with dimethyl acetylenedicarboxylate and maleic anhydride
  作者：Wayland E. Noland、Venkataraman Kameswaran、Lawrence L. Landucci

  DOI：10.1021/jo01311a003

  日期：1980.11
• NOLAND W. E.; KAMESWARAN V.; LANDUCCI L. L., J. ORG. CHEM.,1980, 45, NO 23, 4564-4572
  作者：NOLAND W. E.、 KAMESWARAN V.、 LANDUCCI L. L.

  DOI：——

  日期：——